Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
354 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mantle Cell Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Mantle Cell Lymphoma Overview 9 Therapeutics Development 10 Pipeline Products for Mantle Cell Lymphoma - Overview 10 Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 11 Mantle Cell Lymphoma - Therapeutics under Development by Companies 12 Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16 Mantle Cell Lymphoma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Mantle Cell Lymphoma - Products under Development by Companies 20 Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 24 Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 25 AB Science SA 25 AbbVie Inc. 26 Acetylon Pharmaceuticals, Inc. 27 Actinium Pharmaceuticals, Inc. 28 Advancell 29 Affimed Therapeutics AG 30 Amgen Inc. 31 Astellas Pharma Inc. 32 Astex Pharmaceuticals, Inc. 33 Bayer AG 34 Bristol-Myers Squibb Company 35 Celgene Corporation 36 Cellular Biomedicine Group, Inc. 37 Eisai Co., Ltd. 38 Eli Lilly and Company 39 EpiZyme, Inc. 40 Genentech, Inc. 41 Gilead Sciences, Inc. 42 GlaxoSmithKline Plc 43 Hutchison MediPharma Limited 44 ImmunoGen, Inc. 45 Immunomedics, Inc. 46 Incyte Corporation 47 Infinity Pharmaceuticals, Inc. 48 Johnson & Johnson 49 Karyopharm Therapeutics, Inc. 50 LFB S.A. 51 MedImmune, LLC 52 Merck & Co., Inc. 53 Millennium Pharmaceuticals, Inc. 54 MorphoSys AG 55 Nordic Nanovector ASA 56 Novartis AG 57 Onconova Therapeutics, Inc. 58 Onyx Pharmaceuticals, Inc. 59 Pfizer Inc. 60 Pharmacyclics, Inc. 61 Portola Pharmaceuticals, Inc. 62 Seattle Genetics, Inc. 63 Selvita SA 64 Sorrento Therapeutics, Inc. 65 Stemline Therapeutics, Inc. 66 TG Therapeutics, Inc. 67 Mantle Cell Lymphoma - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Combination Products 69 Assessment by Target 70 Assessment by Mechanism of Action 74 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 13197 - Drug Profile 82 AB-8779 - Drug Profile 84 abemaciclib - Drug Profile 85 abexinostat hydrochloride - Drug Profile 86 acadesine - Drug Profile 88 acalisib - Drug Profile 90 ACP-196 - Drug Profile 91 ACY-775 - Drug Profile 93 AFM-11 - Drug Profile 95 agatolimod sodium - Drug Profile 96 alisertib - Drug Profile 99 AMG-319 - Drug Profile 103 ASN-002 - Drug Profile 104 AT-7519 - Drug Profile 105 bendamustine hydrochloride - Drug Profile 108 Betalutin - Drug Profile 111 BLyS-gel - Drug Profile 113 BMS-986016 - Drug Profile 114 buparlisib hydrochloride - Drug Profile 115 carfilzomib - Drug Profile 119 CBM-C19.1 - Drug Profile 123 CBM-C20.1 - Drug Profile 124 CC-122 - Drug Profile 125 Cell Therapy for Oncology - Drug Profile 127 Cell Therapy to Target CD19 for Oncology - Drug Profile 128 Cell Therapy to Target ROR1 for Oncology - Drug Profile 129 cerdulatinib - Drug Profile 130 copanlisib hydrochloride - Drug Profile 131 daratumumab - Drug Profile 135 denintuzumab mafodotin - Drug Profile 138 duvelisib - Drug Profile 139 E-7449 - Drug Profile 141 entospletinib - Drug Profile 142 epratuzumab - Drug Profile 143 EPZ-015666 - Drug Profile 148 HMPL-523 - Drug Profile 149 ibrutinib - Drug Profile 150 ibrutinib + ublituximab + TGR-1202 - Drug Profile 157 idelalisib - Drug Profile 158 IGN-002 - Drug Profile 161 IMGN-529 - Drug Profile 162 IMMU-114 - Drug Profile 164 INA-01 - Drug Profile 165 INCB-39110 - Drug Profile 166 INCB-40093 - Drug Profile 168 inebilizumab - Drug Profile 169 ixazomib citrate - Drug Profile 171 JNJ-64052781 - Drug Profile 175 lenalidomide - Drug Profile 176 MEDI-0680 - Drug Profile 181 MEDI-551 + MEDI-0680 - Drug Profile 182 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 183 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 184 MOR-208 - Drug Profile 185 ON-123300 - Drug Profile 187 ONC-201 - Drug Profile 188 pevonedistat hydrochloride - Drug Profile 191 polatuzumab vedotin - Drug Profile 193 ribociclib - Drug Profile 195 SEL-120 - Drug Profile 198 selinexor - Drug Profile 200 SGN-CD70A - Drug Profile 206 SL-101 - Drug Profile 207 Small Molecule for Mantle Cell Lymphoma - Drug Profile 208 temsirolimus - Drug Profile 209 TGR-1202 - Drug Profile 211 tisagenlecleucel-T - Drug Profile 213 tretinoin - Drug Profile 216 ublituximab - Drug Profile 217 venetoclax - Drug Profile 219 vorinostat - Drug Profile 222 Mantle Cell Lymphoma - Recent Pipeline Updates 226 Mantle Cell Lymphoma - Dormant Projects 333 Mantle Cell Lymphoma - Discontinued Products 335 Mantle Cell Lymphoma - Product Development Milestones 336 Featured News & Press Releases 336 Appendix 348 Methodology 348 Coverage 348 Secondary Research 348 Primary Research 348 Expert Panel Validation 348 Contact Us 348 Disclaimer 349
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H2 2015 15 Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2015 16 Number of Products under Development by Companies, H2 2015 18 Number of Products under Development by Companies, H2 2015 (Contd..1) 19 Number of Products under Development by Companies, H2 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2015 21 Comparative Analysis by Late Stage Development, H2 2015 22 Comparative Analysis by Clinical Stage Development, H2 2015 23 Comparative Analysis by Early Stage Development, H2 2015 24 Products under Development by Companies, H2 2015 25 Products under Development by Companies, H2 2015 (Contd..1) 26 Products under Development by Companies, H2 2015 (Contd..2) 27 Products under Development by Companies, H2 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2015 29 Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2015 30 Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H2 2015 31 Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 32 Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 33 Mantle Cell Lymphoma - Pipeline by Advancell, H2 2015 34 Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 35 Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2015 36 Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 37 Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 38 Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2015 39 Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 40 Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2015 41 Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 42 Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 43 Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2015 44 Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 45 Mantle Cell Lymphoma - Pipeline by Genentech, Inc., H2 2015 46 Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 47 Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 48 Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 49 Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 50 Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 51 Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2015 52 Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 53 Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015 54 Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 55 Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2015 56 Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015 57 Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 58 Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 59 Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2015 60 Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 61 Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2015 62 Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2015 63 Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 64 Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H2 2015 65 Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 66 Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 67 Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 68 Mantle Cell Lymphoma - Pipeline by Selvita SA, H2 2015 69 Mantle Cell Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 70 Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015 71 Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 72 Assessment by Monotherapy Products, H2 2015 73 Assessment by Combination Products, H2 2015 74 Number of Products by Stage and Target, H2 2015 76 Number of Products by Stage and Mechanism of Action, H2 2015 80 Number of Products by Stage and Route of Administration, H2 2015 84 Number of Products by Stage and Molecule Type, H2 2015 86 Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 231 Mantle Cell Lymphoma - Dormant Projects, H2 2015 338 Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2015 339 Mantle Cell Lymphoma - Discontinued Products, H2 2015 340
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
